𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer

✍ Scribed by Vanna Chiarion-Sileni; Roberto Innocente; Raffaele Cavina; Alberto Ruol; Luigi Corti; Jacopo Pigozzo; Paola Del Bianco; Uberto Fumagalli; Armando Santoro; Ermanno Ancona

Publisher
Springer
Year
2008
Tongue
English
Weight
396 KB
Volume
63
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II trial of 5-fluorouracil, leucov
Phase II trial of 5-fluorouracil, leucovorin, interferon-Ξ±-2a, and cisplatin as neoadjuvant chemotherapy for locally advanced esophageal carcinoma
✍ Barbara K. Temeck; James E. Liebmann; Christopher Theodossiou; Seth M. Steinberg πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 635 KB

## BACKGROUND. Most patients with esophageal carcinoma present with locally advanced disease and a poor prognosis. Surgery or radiation provides palliation for locally advanced esophageal carcinoma. The role of neoadjuvant therapy remains to be defined. We administered neoadjuvant chemotherapy cons

A phase II trial of weekly high dose con
A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer
✍ Enrique Aranda; AndrΓ©s Cervantes; Javier Dorta; Esperanza Blanco; Carlos FernΓ‘nd πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 419 KB πŸ‘ 2 views

Background. In a previous Phase I1 trial, the authors showed that a weekly continuous infusion of 5-fluorouracil (5-FU) at a dose of 3.5 g/mz for 48 hours is an active treatment for advanced colorectal cancer. The overall response rate was 38.5%, and the median survival was 12 months. These data wer